GENRYZON contains somatrogon, a long-acting recombinant human growth hormone analog. Unlike traditional somatropin, it provides extended activity, reducing injection frequency.
It stimulates bone and muscle growth, regulates metabolism, and supports normal physical development.
Recommended for:
Somatrogon is an innovative therapy with strong clinical evidence.
Studies show:
It has been evaluated in international clinical trials and approved for growth hormone deficiency treatment.
The drug is indicated for growth disorders.
Main indications:
It works by replacing growth hormone and stimulating anabolic processes in the body.
The medication is administered subcutaneously using a prefilled pen. It is typically injected once weekly, offering greater convenience compared to daily therapies. Dosage is individualized based on patient weight and clinical response. Injection sites should be rotated regularly.
